In the past, it was difficult for new and essential drugs to be included in the insurance list. But faster adjustment means drug companies do not have to worry about their medicines being shelved so long as they are quality medicines. This will encourage pharmaceutical enterprises to increase investment in R&D, make innovations and strive to achieve a competitive advantage of high quality and low price. However, those pharmaceutical companies that still refuse to give up old practices are bound to be punished and eventually eliminated by the market.